• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硝酸异山梨酯还是硝苯地平:在贲门失弛缓症的药物治疗中哪种更优?

Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia?

作者信息

Bortolotti M, Coccia G, Brunelli F, Sarti P, Mazza M, Bagnato F, Barbara L

机构信息

Divisione di Gastroenterologia, Ospedale Galliera, Genova, Italy.

出版信息

Ital J Gastroenterol. 1994 Oct-Nov;26(8):379-82.

PMID:7703511
Abstract

Oesophageal motor activity was recorded manometrically with a low compliance system in 16 patients with achalasia and a slightly dilated oesophagus. After a basal recording period, nifedipine 20 mg was given sublingually to 9 patients and isosorbide dinitrate 5 mg to another 7 patients. Lower oesophageal sphincter pressure (LESp) and oesophageal body pressure wave amplitude were measured for 60 min after drug administration. Both drugs decreased LESp and pressure wave amplitude, but the effect of isosorbide dinitrate was faster and more intense than that of nifedipine. There was a lower inhibitory effect of nifedipine on the amplitude of pressure waves than on LESp, while isosorbide dinitrate inhibited with a similar intensity both LESp and pressure waves.

摘要

使用低顺应性系统通过测压法记录了16例贲门失弛缓症且食管轻度扩张患者的食管运动活动。在基础记录期后,9例患者舌下含服20毫克硝苯地平,另外7例患者舌下含服5毫克硝酸异山梨酯。给药后60分钟测量食管下括约肌压力(LESp)和食管体压力波幅度。两种药物均降低了LESp和压力波幅度,但硝酸异山梨酯的作用比硝苯地平更快、更强。硝苯地平对压力波幅度的抑制作用低于对LESp的抑制作用,而硝酸异山梨酯对LESp和压力波的抑制强度相似。

相似文献

1
Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia?硝酸异山梨酯还是硝苯地平:在贲门失弛缓症的药物治疗中哪种更优?
Ital J Gastroenterol. 1994 Oct-Nov;26(8):379-82.
2
Short report: comparison of the effects of sublingual nifedipine and isosorbide dinitrate on oesophageal emptying in patients with Chagasic achalasia.简短报告:比较舌下含服硝苯地平和硝酸异山梨酯对恰加斯病性贲门失弛缓症患者食管排空的影响。
Aliment Pharmacol Ther. 1992 Aug;6(4):507-12. doi: 10.1111/j.1365-2036.1992.tb00565.x.
3
Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.硝酸异山梨酯和硝苯地平治疗贲门失弛缓症:临床、测压及放射性核素评估
Gastroenterology. 1982 Nov;83(5):963-9.
4
[Clinical effect of nifedipine in patients with achalasia].硝苯地平对贲门失弛缓症患者的临床疗效
Nihon Heikatsukin Gakkai Zasshi. 1982 Mar;18(1):39-43.
5
Effect of isosorbide dinitrate and atropine on the lower esophageal sphincter pressure in Chagasic patients.硝酸异山梨酯和阿托品对恰加斯病患者食管下括约肌压力的影响。
Acta Physiol Pharmacol Latinoam. 1988;38(2):151-8.
6
Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions.硝苯地平对贲门失弛缓症及高振幅蠕动性食管收缩患者的影响。
JAMA. 1984 Oct 5;252(13):1733-6.
7
Clinical and manometric effects of nifedipine in patients with esophageal achalasia.硝苯地平对贲门失弛缓症患者的临床及测压效果
Gastroenterology. 1981 Jan;80(1):39-44.
8
Comparison of the effects of sublingual isosorbide dinitrate and cardiomyotomy on esophageal emptying in patients with chagasic megaesophagus.硝酸异山梨酯舌下含服与贲门肌切开术对恰加斯病性巨食管患者食管排空影响的比较。
Arq Gastroenterol. 1994 Apr-Jun;31(2):47-51.
9
[The esophagus in Chagas' disease: physiologic, pharmacologic and clinical studies].[恰加斯病中的食管:生理、药理及临床研究]
Arq Gastroenterol. 1987 Jul-Dec;24(3-4):177-83.
10
[Effect of isosorbide dinitrate on esophageal emptying of chagasic megaesophagus: a therapeutic proposal?].[硝酸异山梨酯对恰加斯病性巨食管食管排空的影响:一项治疗建议?]
Arq Gastroenterol. 1990 Jul-Sep;27(3):113-4.

引用本文的文献

1
Problems with repairing gut sphincters malfunctions.修复肠道括约肌功能障碍存在的问题。
World J Gastrointest Surg. 2024 Aug 27;16(8):2396-2408. doi: 10.4240/wjgs.v16.i8.2396.
2
Clinical characteristics and manometric findings of esophageal achalasia-a systematic review regarding differences among three subtypes.食管失弛缓症的临床特征和测压结果——三种亚型差异的系统综述
J Smooth Muscle Res. 2023;59:14-27. doi: 10.1540/jsmr.59.14.
3
2019 Seoul Consensus on Esophageal Achalasia Guidelines.《2019年首尔贲门失弛缓症指南共识》
J Neurogastroenterol Motil. 2020 Apr 30;26(2):180-203. doi: 10.5056/jnm20014.
4
An Overview of Achalasia and Its Subtypes.贲门失弛缓症及其亚型概述。
Gastroenterol Hepatol (N Y). 2017 Jul;13(7):411-421.
5
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.贲门失弛缓症治疗的药物疗法:现状、挑战与未来方向
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):145-55. doi: 10.4292/wjgpt.v6.i4.145.
6
Idiopathic (primary) achalasia: a review.特发性(原发性)贲门失弛缓症:综述
Orphanet J Rare Dis. 2015 Jul 22;10:89. doi: 10.1186/s13023-015-0302-1.
7
Advances in the treatment of achalasia.贲门失弛缓症的治疗进展
Curr Treat Options Gastroenterol. 2014 Mar;12(1):49-58. doi: 10.1007/s11938-013-0007-2.
8
Management of achalasia.贲门失弛缓症的管理
Clin Exp Gastroenterol. 2011;4:33-41. doi: 10.2147/CEG.S11593. Epub 2011 Feb 25.
9
A controversy that has been tough to swallow: is the treatment of achalasia now digested?一个难以咽下的争议:贲门失弛缓症的治疗现在是否被接受了?
J Gastrointest Surg. 2010 Feb;14 Suppl 1(Suppl 1):S33-45. doi: 10.1007/s11605-009-1013-5. Epub 2009 Sep 17.
10
Idiopathic (primary) achalasia.特发性(原发性)贲门失弛缓症。
Orphanet J Rare Dis. 2007 Sep 26;2:38. doi: 10.1186/1750-1172-2-38.